Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Abstract 3679
TAK-243 was suggested to be used at 1-10 µM final concentration in vitro and in cellular assays
PubMed PMID: 12723461
InChi: InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7
4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1
NLG919 (RG6078) - IDO Inhibitor. CAS# 1402836-58-1 0172 Abstract 3679NLG919, CAS No. 1402836 58 1, is a potent, selective and orally bioavailable IDO (indoleamine (2, 3) dioxygenase) pathway inhibitor with Ki ~7 nM (EC50 ~75 nM) in vitro and in cell based assays. Oral administration of NLG919 reduces the [Kyn] in plasma and tissue by ~ 50%. Using human IDO+ pDCs in allogeneic MLR reactions, NLG919 potently blocked IDO induced T cell suppression and restored robust T cell responses with an EC50 ~90 nM. NLG919 abrogated
US$ 36.90
US$ 17.90
US$ 15.90
US$ 24.90
US$ 12.90
US$ 15.90
US$ 12.90